Special Issue

Multisystem Crosstalk in Health and Disease

Message from the Guest Editor

Recent advances in biomedicine demonstrate that health and disease arise from dynamic crosstalk among multiple biological systems; however, substantial knowledge gaps remain in connecting these interactions across scales, from molecular pathways to whole-body physiology. This Special Issue aims to integrate diverse research perspectives to advance a holistic understanding of health. We welcome submissions on foundational mechanisms, such as signaling networks bridging different systems, as well as translational studies identifying biomarkers and interventional strategies targeting multisystem interactions. In addition, we invite clinical investigations into how immune-metabolic dysregulation contributes to disease pathogenesis and novel therapeutic approaches. By illuminating the roles of systemic crosstalk, this issue seeks to uncover underexplored links and inspire innovative strategies that ultimately improve outcomes in chronic diseases and complex conditions.

Guest Editor

Dr. Mehmet Bostancıklıoğlu

Departments of Endocrinology, Diabetes and Nutrition Center, Université Catholique de Louvain (UCLouvain), Brussels, Belgium

Deadline for manuscript submissions

28 February 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/233512

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).